Concur Technologies BREAKING Revenue Records and 4 Stock Analyses Turning Heads

Gilead Sciences Inc. (NASDAQ:GILD): According to Deutsche Bank, Bristol-Myers’ (NYSE:BMY) suspended nucleotide polymerase inhibitor study will increase Gilead’s lead in the development of a treatment for hepatitis C. The firm maintains a Buy rating and increased its price target on the stock.

Don’t Miss: Are These 5 TOP Stock Performers Overbought?

Concur Technologies, Inc. (NASDAQ:CNQR) broke its increasing quarterly revenue guidance, according to Piper Jaffray, by guiding Q4 revenue to 24 percent growth, below consensus of 26 percent. Piper adds that Concur’s Q3 revenue, earnings, and billings all show lower growth rates than in Q2. The firm views the stock as fairly valued, and it maintains a Neutral rating on the stock.

Harley-Davidson, Inc. (NYSE:HOG) price target was reduced by Citigroup after the company’s Q2 results. The firm keeps a Buy rating on the stock.

Arkansas Best Corporation (NASDAQ:ABFS): According to Citigroup, the Federal District Court’s decision for the dismissal of Arkansas Best’s $750 million lawsuit against YRC Worldwide (NASDAQ:YRCW) and the International Brotherhood of Teamster removes a main source of upside potential. Citi thinks that the decision minimizes the possibility for meaningful labor cost adjustments at Arkansas Best. The firm keeps a Neutral rating on the stock.

Gilead Sciences Inc. (NASDAQ:GILD) shares are expected by Citigroup to trade up 10 percent to 15 percent on news that Bristol-Myers (NYSE:BMY) halted the  development of Inhibitex’s nuc because of concerns regarding patient safety. Citi notes that Gilead now has the only late stage nuc for Hepatitis C treatment. The firm maintains a Buy rating on the stock.

Don’t Miss: Apple REIMAGINES the iPad.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.